Shanghai Pharmaceuticals (HKG:2607, SHA:601607) plans to transfer its entire 30% holdings in its subsidiary, Sino-American Shanghai Squibb Pharmaceutical, for not lower than 1.02 billion yuan, according to a Shanghai bourse filing on Thursday.
The equity will be listed on a property rights exchange.